Drug intelligence / Profile preview

RO6806127

Development stage: Phase 1
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

RO6806127 is an investigational small molecule drug developed by Hoffmann-La Roche for potential use in the treatment of schizophrenia. It acts as a modulator of the metabotropic glutamate receptor 5 (mGluR5), stimulating glutamate-mediated neurotransmission in the brain. Dysfunctional glutamatergic transmission is implicated in the pathophysiology of schizophrenia, and mGluR5 modulation represents a novel therapeutic approach. The compound was evaluated in phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy male volunteers. Development was discontinued due to challenges related to its long half-life and adverse events at higher doses[2][3][5].

Other names: RG7342RG-7342RG 7342

Targets

GRM5 (Metabotropic glutamate receptor 5)

Beyond the preview

Go deeper on RO6806127.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO6806127.

Explore the full profile